Alglucosidase Alfa Pompe Safety Sub-Registry

CompletedOBSERVATIONAL
Enrollment

110

Participants

Timeline

Start Date

March 20, 2015

Primary Completion Date

April 20, 2021

Study Completion Date

April 20, 2021

Conditions
Pompe Disease
Interventions
BIOLOGICAL

alglucosidase alfa

Alglucosidase alfa IV infusion of 20 mg/kg; qow

Trial Locations (18)

3000

Investigational Site Number 056002, Leuven

Investigational Site Number 056003, Leuven

9000

Investigational Site Number 056001, Ghent

10043

Investigational Site Number 158001, Taipei

12808

Investigational Site Number 203001, Prague

15213

Investigational Site Number 840014, Pittsburgh

17033

Investigational Site Number 840004, Hershey

20133

Investigational Site Number 380005, Milan

22030

Investigational Site Number 840001, Fairfax

25123

Investigational Site Number 380001, Brescia

27710

Investigational Site Number 840002, Durham

35128

Investigational Site Number 380004, Padua

84113

Investigational Site Number 840008, Salt Lake City

85013

Investigational Site Number 840016, Phoenix

98125

Investigational Site Number 380006, Messina

06120

Investigational Site Number 276002, Halle

09126

Investigational Site Number 380002, Cagliari

00168

Investigational Site Number 380003, Roma

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT01710813 - Alglucosidase Alfa Pompe Safety Sub-Registry | Biotech Hunter | Biotech Hunter